Atossa Therapeutics Announces Expanded Research Agreement With Weill Cornell Medicine

Seeking AlphaApr 29 21:32

HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $4 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates Atossa Therapeutics with a Buy and maintains $4 price target.

Analyst UpgradesApr 16 23:01

Atossa Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 150.78% HC Wainwright & Co. → $4 Reiterates Buy → Buy 04/02/2024 150.78% HC Wainwright & Co. $4

BenzingaApr 16 22:59

Promising Synergies: Atossa Therapeutics' Advances in ER+/HER2- Breast Cancer Treatment

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Atossa Therapeutics (ATOS – Research Report) today and set a price target of $4.00.

TipRanksApr 16 00:05

Atossa Therapeutics And Quantum Leap Healthcare Initiates I-SPY 2 Clinical Trial To Evaluate (Z)-Endoxifen In Combination With Abemaciclib In Women With ER+/HER2- Breast Cancer

The new study arm will enroll approximately 20 women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) invasive breast cancer. Participa

BenzingaApr 15 20:39

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination With Abemaciclib (VERZENIO) in Women With ER+/HER2- Breast Cancer

The new study arm will enroll approximately 20 women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) invasive breast cancer.

Globe NewswireApr 15 20:30